Author:
Plaisance Connor J,Borne Grant E,Daniel Charles P,Wagner Maxwell J,Shelvan Anitha,Mathew Jibin,Ahmadzadeh Shahab,Paladini Antonella,Varrassi Giustino,Shekoohi Sahar,Kaye Alan D
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Community-acquired pneumonia and hospital-acquired pneumonia;Lanks CW;Med Clin North Am,2019
2. New antibiotics for hospital-acquired pneumonia and ventilator-associated pneumonia;Bassetti M;Semin Respir Crit Care Med,2022
3. In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany;Kresken M;Int J Antimicrob Agents,2020
4. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative bacilli from North America and Europe, including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study);Hackel MA;Antimicrob Agents Chemother,2017
5. In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017-2020;Lee YL;Int J Antimicrob Agents,2021